Author

In-Ho Kim

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Initial Enfortumab Vedotin Dose Reduction and Outcomes in Pretreated Advanced Urothelial Carcinoma.

Importance Initial enfortumab vedotin (EV) dose selection is increasingly relevant in advanced urothelial carcinoma (UC). Reduced starting doses may be selected for some patients, but their associations with clinical outcomes and tolerability remain uncertain. Objective To evaluate the association of physician-select...

In-Ho Kim, Chang Gon Kim, Jungmin Jo et al. · JAMA Network Open · 0 citations

Open access Oct 2025

Real-World Efficacy of First-Line Nivolumab Plus Ipilimumab and Its Practical Predictive Biomarkers in Advanced Renal Cell Carcinoma: First Analysis from RENOIR Study (KCSG GU22-13)

Purpose We investigated the real-world efficacy of first-line nivolumab plus ipilimumab (NI) and its predictive clinicopathological biomarkers in patients with advanced renal cell carcinoma (aRCC). Materials and Methods We retrospectively analyzed 466 patients with aRCC who started first-line NI between 2019 and 2023 a...

Jwa Hoon Kim, Sang Joon Shin, W. K. Bae et al. · Cancer research and treatmen... · 0 citations

Open access Oct 2026

Multi-Cycle Dosimetry of the Albumin-Binding Prostate-Specific Membrane Antigen Ligand [177Lu]Ludotadipep in Metastatic Androgen Pathway Modulator-Resistant Prostate Cancer with Adjusted Red Marrow Modeling

Purpose: This dosimetry study aimed to evaluate the organ-absorbed doses and safety profile of multiple doses of [177Lu]Ludotadipep, a novel PSMA-targeted radiopharmaceutical with an albumin-binding motif, in patients with metastatic androgen pathway modulator-resistant (mAPMR) prostate cancer. Methods: Twenty patients...

Seunggyun Ha, J. O, Chansoo Park et al. · Pharmaceutics · 0 citations